<DOC>
	<DOCNO>NCT02069093</DOCNO>
	<brief_summary>Open-label , Phase II study Stomatitis prevention steroid-based mouthwash Post-menopausal woman ER+ , HER2- Metastatic Locally Advanced Breast Cancer</brief_summary>
	<brief_title>Open-label , Phase II Study Stomatitis Prevention With Steroid-based Mouthwash Post-menopausal Women With Estrogen-receptor-positive ( ER+ ) , Human Epidermal Growth Factor Receptor 2 ( HER2 ) - Metastatic Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Adult woman &gt; 18 year age metastatic locally advanced breast cancer amenable curative treatment surgery radiotherapy 2 . Histological cytological confirmation hormonereceptor positive ( HR+ ) human epidermal growth factor receptor 2 negative ( HER2 ) breast cancer 3 . Postmenopausal woman . Postmenopausal status define either : Age ≥ 55 year one year amenorrhea Age &lt; 55 year one year amenorrhea , estradiol assay &lt; 20 pg/ml Surgical menopause bilateral oophorectomy Note : Ovarian radiation treatment luteinizing hormonereleasing hormone ( LHRH ) agonist ( goserelin acetate leuprolide acetate ) permit induction ovarian suppression 4 . Patient assess treat physician appropriate candidate everolimus plus exemestane therapy treatment advance metastatic breast cancer plan prescribe everolimus 10mg PO QD combination exemestane 25mg PO QD 5 . Patient must start everolimus 10mg plus exemestane 25mg treatment Cycle 1 Day 1 trial 6 . ECOG Performance status ≤ 2 7 . Adequate renal function : serum creatinine ≤ 1.5x ULN ; 8 . Willingness selfreport level oral pain use Visual Analog Scale ( VAS ) Normalcy Diet Scale ( NDS ) throughout stomatitis event , require patient diary . At baseline , patient 's selfreported oral pain level , use VAS , must 0 normalcy diet scale score ≥ 60 9 . Signed informed consent obtain prior screening procedure Exclusion criterion : 1 . Patients currently receive anticancer therapy ( except biphosphonate , denosumab ) ; 2 . Patients currently stomatitis/oral mucositis/mouth ulcer ; 3 . Known intolerance hypersensitivity everolimus rapamycin analog ( e.g . sirolimus , temsirolimus ) ; 4 . Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral Everolimus ; 5 . Uncontrolled diabetes mellitus define HbA1c &gt; 8 % despite adequate therapy . Patients known history impair fast glucose diabetes mellitus ( DM ) may include , however blood glucose antidiabetic treatment must monitor closely throughout trial adjust necessary ; 6 . Patients severe and/or uncontrolled medical condition : Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior start everolimus , serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease Symptomatic congestive heart failure New York heart Association Class III IV active ( acute chronic ) uncontrolled severe infection , liver disease cirrhosis , decompensated liver disease ( except Hep B Hep C positive patient ) Known severely impair lung function ( spirometry DLCO 50 % less normal O2 saturation 88 % less rest room air ) active , bleeding diathesis ; 7 . Chronic treatment corticosteroid immunosuppressive agent . Topical inhale corticosteroid allow ; 8 . Known history HIV seropositivity ; 9 . Patients receive live attenuate vaccine within 1 week start everolimus study . Patient also avoid close contact others receive live attenuate vaccine . Examples live attenuate vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella TY21a typhoid vaccine ; 10 . Patients history another primary malignancy , exception : nonmelanoma skin cancer , carcinoma situ cervix , uterus , breast patient disease free ≥3 year ; 11 . Patients history noncompliance medical regimen consider potentially unreliable able complete entire study patient diary ; 12 . Patients currently part clinical investigation resolution acute toxic effect prior anticancer therapy NCI CTCAE version 4.03 Grade 1 ( except alopecia toxicity consider safety risk patient investigator 's discretion ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>